Arrowhead Pharmac…
USUSDArrowhead Pharmaceuticals Inc (US:ARWR) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 2. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O podjetju
- Spletna stran
- arrowheadpharma.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sedež
- Pasadena, United States
- Izvršni direktor
- Dr. Christopher R. Anzalone Ph.D.
- Zaposleni
- 711
- Ustanovljena
- 2004
- Delnice v obtoku
- 141.25 mio. na dan 2026-07-30
- Prosto prenosljive delnice
- 122.45 mio.
- Tržna kapitalizacija
- 9.22 mrd. USD
- Notranje osebe
- 3.66%
- Institucionalni vlagatelji
- 85.47%
- Panoga (SIC)
- Pharmaceutical Preparations
- ISIN
- US04280A1007
- LEI
- 549300O3CSB8T7OZ3D66
Opis
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Dividende
Ni bilo najdenih izplačil dividend (preverjeno 09.10.2026). Podjetje verjetno ne izplačuje dividend.
Novice ta teden
Novic s spletnega mesta podjetja še ni.
Največji imetniki
| Imetnik | Delež | Delnice | Datum poročila |
|---|---|---|---|
| Blackrock Inc. | 10.53% | 14.83 mio. | 2026-06-30 |
| Avoro Capital Advisors L… | 8.06% | 11.36 mio. | 2026-06-30 |
| FMR, LLC | 5.71% | 8.04 mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.51% | 6.35 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 4.34% | 6.11 mio. | 2026-06-30 |
| State Street Corporation | 4.04% | 5.69 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 3.5% | 4.93 mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.01% | 4.25 mio. | 2026-06-30 |
| NORGES BANK | 2.77% | 3.9 mio. | 2026-06-30 |
| Invesco Ltd. | 2.76% | 3.88 mio. | 2026-06-30 |
| ANZALONE CHRISTOPHER RIC… | ≈2.69% | 3.79 mio. | 2026-01-02 |
| Geode Capital Management… | 2.51% | 3.53 mio. | 2026-06-30 |
| Fred Alger Management, L… | 2.34% | 3.3 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.18% | 3.07 mio. | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.81% | 2.55 mio. | 2026-07-31 |
| Invesco Exchange-Traded… | 1.27% | 1.79 mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.26% | 1.77 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 1.61 mio. | 2026-06-30 |
| SPDR SERIES TRUST-State… | 1.05% | 1.48 mio. | 2026-08-31 |
| SPDR S&P MIDCAP 400 ETF… | 0.73% | 1.03 mio. | 2026-08-31 |
| iShares Trust-iShares Bi… | 0.69% | 968 738 | 2026-07-31 |
| O'BRIEN PATRICK C (Chief… | ≈0.39% | 547 408 | 2026-01-06 |
| MYSZKOWSKI KENNETH ALLEN… | ≈0.32% | 455 433 | 2025-01-07 |
| HAMILTON JAMES C (Office… | ≈0.16% | 226 958 | 2026-04-23 |
| APEL DANIEL JOSEPH (Chie… | ≈0.12% | 162 905 | 2026-04-22 |
| GIVEN DOUGLAS BRUCE (Dir… | ≈0.09% | 124 167 | 2024-12-17 |
| PERRY MICHAEL S (Directo… | ≈0.08% | 111 459 | 2026-08-18 |
| FERRARI MAURO (Director) | ≈0.05% | 69 053 | 2025-12-26 |
| WADDILL WILLIAM D (Direc… | ≈0.04% | 56 563 | 2025-12-19 |
| LU HONGBO B (Director) | ≈0.04% | 52 012 | 2026-05-12 |
